Cancer Letters
Volume 228, Issue 1 , Pages 5-11 , 18 October 2005

A review of DNA microarray analysis of human neuroblastomas

  • Miki Ohira

      Affiliations

    • Division of Biochemistry, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuoh-ku, Chiba 260-8717, Japan
    • ,
  • Shigeyuki Oba

      Affiliations

    • Graduate School of Information Science, Nara Institute of Science and Technology, Ikoma 630-0192, Japan
    • ,
  • Yoko Nakamura

      Affiliations

    • Division of Biochemistry, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuoh-ku, Chiba 260-8717, Japan
    • ,
  • Takahiro Hirata

      Affiliations

    • Hisamitsu Pharmaceutical Co. Inc., Tokyo 100-622, Japan
    • ,
  • Shin Ishii

      Affiliations

    • Graduate School of Information Science, Nara Institute of Science and Technology, Ikoma 630-0192, Japan
    • ,
  • Akira Nakagawara

      Affiliations

    • Division of Biochemistry, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuoh-ku, Chiba 260-8717, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 43 264 5431; fax: +81 43 265 4459.

Received 20 December 2004 ,Accepted 12 January 2005.

References 

  1. Bolande RP. The neurocristopathies: a unifying concept of disease arising in neural crest maldevelopment. Hum. Pathol. 1974;5:409–429
  2. Weinstein JL, Katzenstein HM, Cohn SL. Advances in the diagnosis and treatment of neuroblastoma. Oncologist. 2003;8:278–292
  3. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N. Engl. J. Med. 1993;328:847–854
  4. Nakagawara A, Azar CG, Scavarda NJ, Brodeur GM. Expression and function of TRK-B and BDNF in human neuroblastomas. Mol. Cell Biol. 1994;14:759–767
  5. Hiyama E, Hiyama K, Yokoyama T, Matsuura Y, Piatyszek MA, Shay JW. Correlating telomerase activity levels with human neuroblastoma outcomes. Nat. Med. 1995;1:249–255
  6. Favrot MC, Combaret V, Lasset C. CD44–a new prognostic marker for neuroblastoma. N. Engl. J. Med. 1993;329
  7. Nakagawara A, Milbrandt J, Muramatsu T, Deuel TF, Zhao H, Cnaan A, et al. Differential expression of pleiotrophin and midkine in advanced neuroblastomas. Cancer Res. 1995;55:1792–1797
  8. Shimono R, Matsubara S, Takamatsu H, Fukushige T, Ozawa M. The expression of cadherins in human neuroblastoma cell lines and clinical tumors. Anticancer Res. 2000;20:917–923
  9. Tanaka T, Sugimoto T, Sawada T. Prognostic discrimination among neuroblastomas according to Ha-ras/trk A gene expression: a comparison of the profiles of neuroblastomas detected clinically and those detected through mass screening. Cancer. 1998;83:1626–1633
  10. Nagata T, Takahashi Y, Asai S, Ishii Y, Mugishima H, Suzuki T, et al. The high level of hCDC10 gene expression in neuroblastoma may be associated with favorable characteristics of the tumor. J. Surg. Res. 2000;92:267–275
  11. Islam A, Kageyama H, Takada N, Kawamoto T, Takayasu H, Isogai E, et al. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene. 2000;19:617–623
  12. Hailat N, Keim DR, Melhem RF, Zhu XX, Eckerskorn C, Brodeur GM, et al. High levels of p19/nm23 protein in neuroblastoma are associated with advanced stage disease and with N-myc gene amplification. J. Clin. Invest. 1991;88:341–345
  13. Leone A, Seeger RC, Hong CM, Hu YY, Arboleda MJ, Brodeur GM, et al. Evidence for nm23 RNA overexpression, DNA amplification and mutation in aggressive childhood neuroblastomas. Oncogene. 1993;8:855–865
  14. Saito-Ohara F, Imoto I, Inoue J, Hosoi H, Nakagawara A, Sugimoto T, et al. PPM1D is a potential target for 17q gain in neuroblastoma. Cancer Res. 2003;63:1876–1883
  15. Ohira M, Morohashi A, Nakamura Y, Isogai E, Furuya K, Hamano S, et al. Neuroblastoma oligo-capping cDNA project: toward the understanding of the genesis and biology of neuroblastoma. Cancer Lett. 2003;197:63–68
  16. Ohira M, Morohashi A, Inuzuka H, Shishikura T, Kawamoto T, Kageyama H, et al. Expression profiling and characterization of 4200 genes cloned from primary neuroblastomas: identification of 305 genes differentially expressed between favorable and unfavorable subsets. Oncogene. 2003;22:5525–5536
  17. Kawamoto T, Ohira M, Hamano S, Hori T, Nakagawara A. High expression of the novel endothelin-converting enzyme genes, Nbla03145/ECEL1alpha and beta, is associated with favorable prognosis in human neuroblastomas. Int. J. Oncol. 2003;22:815–822
  18. Hamano S, Ohira M, Isogai E, Nakada K, Nakagawara A. Identification of novel human neuronal leucine-rich repeat (hNLRR) family genes and inverse association of expression of Nbla10449/hNLRR-1 and Nbla10677/hNLRR-3 with the prognosis of primary neuroblastomas. Int. J. Oncol. 2004;24:1457–1466
  19. Kato C, Miyazaki K, Nakagawa A, Ohira M, Nakamura Y, Ozaki T, et al. Low expression of human tubulin tyrosine ligase and suppressed tubulin tyrosination/detyrosination cycle are associated with impaired neuronal differentiation in neuroblastomas with poor prognosis. Int. J. Cancer. 2004;112:365–375
  20. Roberts SS, Mori M, Pattee P, Lapidus J, Mathews R, O'Malley JP, et al. GABAergic system gene expression predicts clinical outcome in patients with neuroblastoma. J. Clin. Oncol. 2004;22:4127–4134
  21. Khan J, Wei JS, Ringner M, Saal LH, Ladanyi M, Westermann F, et al. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat. Med. 2001;7:673–679
  22. Yamanaka Y, Hamazaki Y, Sato Y, Ito K, Watanabe K, Heike T, et al. Maturational sequence of neuroblastoma revealed by molecular analysis on cDNA microarrays. Int. J. Oncol. 2002;21:803–807
  23. Berwanger B, Hartmann O, Bergmann E, Bernard S, Nielsen D, Krause M, et al. Loss of a FYN-regulated differentiation and growth arrest pathway in advanced stage neuroblastoma. Cancer Cell. 2002;2:377–386
  24. Takita J, Ishii M, Tsutsumi S, Tanaka Y, Kato K, Toyoda Y, et al. Gene expression profiling and identification of novel prognostic marker genes in neuroblastoma. Genes Chromosomes Cancer. 2004;40:120–132
  25. Hiyama E, Hiyama K, Yamaoka H, Sueda T, Reynolds CP, Yokoyama T. Expression profiling of favorable and unfavorable neuroblastomas. Pediatr. Surg. Int. 2004;20:33–38
  26. McArdle L, McDermott M, Purcell R, Grehan D, O'Meara A, Breatnach F, et al. Oligonucleotide microarray analysis of gene expression in neuroblastoma displaying loss of chromosome 11q. Carcinogenesis. 2004;25:1599–1609
  27. Janoueix-Lerosey I, Novikov E, Monteiro M, Gruel N, Schleiermacher G, Loriod B, et al. Gene expression profiling of 1p35-36 genes in neuroblastoma. Oncogene. 2004;23:5912–5922
  28. Wei JS, Greer BT, Westermann F, Steinberg SM, Son CG, Chen QR, et al. Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res. 2004;64:6883–6891
  29. M. Ohira, S. Oba, Y. Nakamura, E. Isogai, S. Kaneko, A. Nakagawa, et al., Expression profiling using a tumor-specific cDNA microarray prediols the prognosis of intermediate-risk neuroblastomas, Cancer Cell 7 (2005) 337-350.
  30. M. Abe, M. Ohira, A. Kaneda, Y. Yagi, S. Yamamoto, Y. Kitano, et al., CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas, Cancer Res., 65 (2005) 828–834.

PII: S0304-3835(05)00360-5

doi: 10.1016/j.canlet.2005.01.054

Cancer Letters
Volume 228, Issue 1 , Pages 5-11 , 18 October 2005

Article Tools